Background: The incidence of rash after aminopenicillin treatment in children with Epstein-Barr Virus (EBV) infection was reported to be 80–100%. A few recent studies suggested that the incidence may be much lower during EBV infection. There are no clear data on the incidence of true drug hypersensitivity among these patients. The aim of this study is to determine the incidence of rash and antibiotic allergy after antibiotic treatment in children with EBV infection. Methods: Drug hypersensitivity was investigated in antibiotic-treated patients with a positive EBV IgM who developed a rash between 2013 and 2016. Results: During the study period, 221 children were diagnosed with EBV infection, and 120 (54.3%) patients were treated with antibiotics during disease. Rash developed in 41 (41/221, 18.6%) patients, and 20 of them (total 120; 16.6%) were treated with antibiotics (most frequently aminopenicillins: 72.5%), and 21 of them (total 101, 20.8%) were not treated with antibiotics (p = 0.43). For 10 of the 20 antibiotic-treated patients with a rash, parents did not consent to an allergy workup. Three of the 10 patients who were tested for drug allergy were proven to have amoxicillin-clavulanate hypersensitivity (30%). Five of the patients without workup reacted after reuse of the suspected drug for infection treatment. Conclusion: In this study, the incidence of drug hyper-sensitivity was much lower than previously reported. Some of the reactions that occur during infectious mononucleosis are transient, and some are true drug hypersensitivity reactions. Thus, these patients should be evaluated with allergy tests before these drugs are used again after EBV infection.

Keywords:
Allergy, Antibiotics, Drug hypersensitivity, Epstein-Barr virus, Rash
1.
Hall LD, Eminger LA, Hesterman KS, Heymann WR: Epstein-Barr virus: dermatologic associations and implications: part I. Mucocutaneous manifestations of Epstein-Barr virus and nonmalignant disorders. J Am Acad Dermatol 2015; 72: 1–19.
2.
Di Lernia V, Mansouri Y: Epstein-Barr virus and skin manifestations in childhood. Int J Dermatol 2013; 52: 1177–1184.
3.
Ónodi-Nagy K, Bata-Csörgő Z, Varga E, Kemeny L, Kinyo A: Antibiotic Induced Cutaneous Rash in Infectious Mononucleosis: Overview of the Literature. J Allergy Ther 2015; 6: 222.
4.
Patel BM: Skin rash with infectious mononucleosis and ampicillin. Pediatrics 1967; 40: 910–911.
5.
Pullen H, Wright N, Murdoch JM: Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 1967; 2: 1176–1178.
6.
McCloskey GL, Massa MC: Cephalexin rash in infectious mononucleosis. Cutis 1997; 59: 251–254.
7.
Le Claire AC, Martin CA, Hoven AD: Rash associated with piperacillin/tazobactam administration in infectious mononucleosis. Ann Pharmacother 2004; 38: 996–998.
8.
Wargo KA, McConnell V, Jennings M: Amoxicillin/telithromycin induced rash in infectious mononucleosis. Ann Pharmaco ther 2005; 39: 1577.
9.
Leung AK, Rafaat M: Eruption associated with amoxicillin in a patient with infectious mononucleosis. Int Journal Dermatol 2003; 42: 553–555.
10.
Chovel-Sella A, Ben Tov A, Lahav E, Mor O, Rudich H, Paret G, Reif S: Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics 2013; 131: 1424–1427.
11.
Jappe U: Amoxicillin-induced exanthema in patients with infectious mononucleosis: allergy or transient immunostimulation? Allergy 2007; 62: 1474–1475.
12.
Renn CN, Straff W, Dorfmüller A, Al-Ma-saoudi T, Merk HF, Sachs B: Amoxicillin-induced exanthema in young adults with infectious mononucleosis: demonstration of drug-specific lymphocyte reactivity. Br J Dermatol 2002; 147: 1166–1170.
13.
Ónodi-Nagy K, Kinyó Á, Meszes A, Garaczi E, Kemény L, Bata-Csörgő Z: Amoxicillin rash in patients with infectious mononucleosis: evidence of true drug sensitization. Allergy Asthma Clin Immunol 2015; 11: 1.
14.
Demoly P, Kropf R, Bircher A, Pichler WJ: Drug hypersensitivity: Questionnaire. EAACI Interest Group on Drug Hypersensitivity. Allergy 1999; 54: 999–1003.
15.
Aberer W, Bircher A, Romano A, Blanca M, Campi M, Fernandez J, Brockow K, Pichler WJ, Demoly P; European Network for Drug Allergy (ENDA); EAACI Interest Group on Drug Hypersensivity: Drug provocation testing in the diagnosis of drug hypersensivity reactions: general considerations. Allergy 2003; 58: 854–863.
16.
Hocqueloux L, Causse X, Valery A, Jandali JC, Maitre, Soin C, Buret J, Ouane F, Niang M, Mille C, Prazuck T, Guinard J, Guigon A: The high burden of hospitalizations for primary EBV infection: a 6-year prospective survey in a French hospital. Clin Microbiol Infect 2015; 21: 1041.e1–e7.
17.
Hocqueloux L, Guinard J, Buret J, Causse X, Guigon A: Do penicillins really increase the frequency of a rash when given during Epstein-Barr Virus primary infection? Clin Infect Dis 2013; 57: 1661–1662.
18.
Nazareth I, Mortimer P, Mc Kendrick GD: Ampicillin sensitivity in infectious mononucleosis-temporary or permanent? Scand J Infect Dis 1972; 4: 229–230.
19.
Vezir E, Dibek Misirlioglu E, Civelek E, Capanoglu M, Guvenir H, Ginis T, Toyran M, Kocabas CN: Direct oral provocation tests in non-immediate mild cutaneous reactions related to beta-lactam antibiotics. Pediatr Allergy Immunol 2016; 27: 50–54.
20.
Webster AW, Thompson RA: The ampicillin rash. Lymphocyte transformation by ampicillin polymer. Clin Exp Immunol 1974; 18: 553–564.
21.
McKenzie H, Parratt D, White RG: IgM and IgG antibody levels to ampicillin in patients with infectious mononucleosis. Clin Exp Immunol 1976; 26: 214–221.
22.
Haverkos HW, Amsel Z, Drotman DP: Adverse virus-drug interactions. Rev Infect Dis 1991; 13: 697–704.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.